Arctic Therapeutics

Executive Summary

Arctic Therapeutics is a clinical-stage biopharmaceutical company leveraging Iceland's unique genetic and genealogical database to identify disease-causing mutations and develop targeted treatments. By analyzing the genomes of the entire Icelandic population across centuries, the company uncovers rare variants linked to common and rare diseases, enabling a precision medicine approach. This platform has led to a pipeline of small molecule and genetic therapies aimed at conditions with high unmet need, including neurodegenerative, metabolic, and inflammatory disorders. The company's ability to correlate genotype with phenotype at population scale provides a significant advantage in target discovery and patient stratification, potentially accelerating drug development timelines and increasing probability of success. Arctic Therapeutics has reached an 'Approved' stage, indicating that at least one of its programs has achieved regulatory approval or a major milestone, validating its platform. The company is now focused on expanding its pipeline and advancing additional candidates into later-stage trials. With a strong foundation in human genetics and a proven ability to translate genetic insights into therapies, Arctic Therapeutics is positioned to address some of the world's most pressing diseases. Its innovative approach, combined with a robust data moat, makes it a compelling player in the precision medicine space.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead program in Alzheimer's disease60% success
• Q2 2027FDA acceptance of IND for second pipeline candidate targeting metabolic disease75% success
• Q1 2027Partnership or licensing deal for genetic database access with major pharma50% success